Keiko Hattori Joins Haemonetics as President of Haemonetics Japan

Thursday, October 18, 2007 General News J E 4
BRAINTREE, Mass., and TOKYO, Oct. 17 HaemoneticsCorporation (NYSE: HAE) is pleased to announce that Keiko Hattori will jointhe Company effective October 22, 2007 as President, Haemonetics Japan. Ms.Hattori will replace Haemonetics Japan's current President, Ryoji Sakai, whopreviously announced plans to retire.

Brian Concannon, Haemonetics' Chief Operating Officer, said, "Ms. Hattorihas tremendous experience and a proven track record for growing businesses inthe Japanese and Asian healthcare markets. She brings a depth of leadership tothe Japan organization and our senior management team. We are very excited tohave someone of her capabilities joining us."

Ms. Hattori's professional background includes positions of increasingresponsibility in sales, marketing, and management at several globalhealthcare companies. She joined Pharmacia in 1985 as Manager of RegulatoryAffairs. She remained with Pharmacia when it was acquired by Amersham andultimately became President of Amersham Biosciences KK. In 2004, whenAmersham was acquired by GE she continued the role. Since then Ms. Hattorihas held positions with increasing responsibility in various GE divisions inthe U.S. and Asia.

Ms. Hattori, age 55, has a BS in Biochemistry from Tokyo University.

Mr. Concannon added, "I'd also like to thank Ryoji Sakai for hissignificant contributions to Haemonetics during his 13 years of service, aswell as for his leadership in transforming our Japanese organization." Mr.Sakai will remain at Haemonetics through fiscal year end as an ExecutiveAdvisor to facilitate a smooth transition.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated toproviding innovative blood management solutions for our customers. Together,our devices and consumables, IT products, and consulting services deliver asuite of business solutions to help our customers improve clinical outcomesand reduce the cost of healthcare for blood collectors, hospitals, andpatients around the world. Our technologies address important medicalmarkets: blood and plasma component collection, the surgical suite, andhospital transfusion services. To learn more about Haemonetics, visit our website at Julie Fallon Tel. (781) 356-9517 Alternate Tel. (617) 320-2401

SOURCE Haemonetics Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Arena Pharmaceuticals Announces Third Quarter 2007...
Stryker Operating Results for Quarter Ended Septem...